Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catheter Precision (VTAK) EBITDA (2017 - 2025)

Catheter Precision has reported EBITDA over the past 9 years, most recently at -$9.9 million for Q4 2025.

  • Quarterly EBITDA fell 223.21% to -$9.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$21.1 million through Dec 2025, down 88.05% year-over-year, with the annual reading at -$21.1 million for FY2025, 88.05% down from the prior year.
  • EBITDA was -$9.9 million for Q4 2025 at Catheter Precision, down from -$3.0 million in the prior quarter.
  • Over five years, EBITDA peaked at -$2.6 million in Q4 2023 and troughed at -$66.5 million in Q1 2023.
  • The 5-year median for EBITDA is -$5.1 million (2022), against an average of -$8.4 million.
  • Year-over-year, EBITDA crashed 1108.14% in 2023 and then soared 96.07% in 2024.
  • A 5-year view of EBITDA shows it stood at -$8.3 million in 2021, then increased by 0.59% to -$8.2 million in 2022, then soared by 68.39% to -$2.6 million in 2023, then decreased by 17.48% to -$3.1 million in 2024, then tumbled by 223.21% to -$9.9 million in 2025.
  • Per Business Quant, the three most recent readings for VTAK's EBITDA are -$9.9 million (Q4 2025), -$3.0 million (Q3 2025), and -$4.7 million (Q2 2025).